NCT06545253Not yet recruiting
A New Diagnostic Paradigm for Retinitis Pigmentosa Secondary to USH2A Pathogenic Variants
Source: ClinicalTrials.gov · Last updated 9 Aug 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Aim of the study is to perform a non-invasive multimodal retinal imaging investigation in a cohort of patients affected by USH2A retinitis pigmentosa (USH2A-RP), in order to develop a new diagnostic paradigm to categorize clinically relevant subgroups. All the procedures will be performed according to normal clinical practice. In addition, a novel quantitative profiling of serum microRNAs will be carried out in order to analyze the clinical importance of microRNA biomarkers in the clinical setting of the disease.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 14 Jul 2024
- Start date
- Aug 2024
- Primary completion date
- Feb 2025
- Lead sponsor
- IRCCS Ospedale San Raffaele
- Diseases
- Retinitis pigmentosa
- NCT number
- NCT06545253
What you commit to
- Study type: Observational
- Planned participants: 60
- From Aug 2024 to the primary completion date, Feb 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- ophthalmologic surgery within the previous six months
Other illness
- any inflammatory, infectious or degenerative eye disease
- uncontrolled systemic, metabolic, autoimmune neuroinflammatory and neurodegenerative disease
Other
- inability to understand and sign the written informed consent form
- media opacities resulting incompatible with good imaging quality
Who the study is looking for
- age \>18 years
- genetically confirmed diagnosis of USH2A-RP
- availability of genetic tests to assess the pathogenic variants
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.